title: Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Behr
authors.forename: Martin
authors.initials: M
authors.lastname: Béhé
authors.forename: Gerald
authors.initials: G
authors.lastname: Kluge
authors.forename: Martin
authors.initials: M
authors.lastname: Gotthardt
authors.forename: Meike L
authors.initials: ML
authors.lastname: Schipper
authors.forename: Stefan
authors.initials: S
authors.lastname: Gratz
authors.forename: Rudolf
authors.initials: R
authors.lastname: Arnold
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Becker
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D000818:Animals; D006801:Humans; D007668:Kidney / Q000293:injuries / Q000528:radiation effects*; D009369:Neoplasms / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D010455:Peptides; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D015282:Octreotide; C106246:Edotreotide